Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00807872 · ClinicalTrials.gov registry record · Phase 1
Radioimmunoimaging of AL Amyloidosis
A Phase 1 study, sponsored by University of Tennessee.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
NCT00807872 is a Phase 1 study that has completed, run by University of Tennessee. The registered enrollment target is 40 participants.
The verdict
NCT00807872, a Phase 1 study, has completed, sponsored by University of Tennessee.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
Study Summary
The purpose of the study is to determine the capability of a radiolabeled amyloid-reactive monoclonal antibody to document the presence and distribution of amyloid deposits by PET/CT imaging in patients with AL amyloidosis.
Interventions
- BIOLOGICAL 124I-labeled monoclonal antibody Mu 11-1F4
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2008-12 |
| Est. Completion | 2013-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00807872
The ClinicalTrials.gov registry entry for NCT00807872 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Tennessee, which has 96 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which 124I-labeled monoclonal antibody Mu 11-1F4 is the first listed.
NCT00807872 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00807872 about?
NCT00807872 is a clinical study titled "Radioimmunoimaging of AL Amyloidosis". The purpose of the study is to determine the capability of a radiolabeled amyloid-reactive monoclonal antibody to document the presence and distribution of amyloid deposits by PET/CT imaging in patients with AL amyloidosis.
What is the current status of trial NCT00807872?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2008-12. Estimated completion is 2013-07.
What interventions are being tested in trial NCT00807872?
The interventions under investigation include: 124I-labeled monoclonal antibody Mu 11-1F4 (BIOLOGICAL).
Who is sponsoring clinical trial NCT00807872?
This trial is sponsored by University of Tennessee, which has 96 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.